{"organizations": [], "uuid": "ede196e9e20a045f6037851d4a2e18f667e7adf0", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-bristol-myers-squibb-says-key-lung/brief-bristol-myers-squibb-says-key-lung-cancer-trial-meets-main-goal-idUSFWN1PV0V1", "country": "US", "domain_rank": 408, "title": "BRIEF-Bristol-Myers Squibb Says Key Lung Cancer Trial Meets Main Goal", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-05T14:19:00.000+02:00", "replies_count": 0, "uuid": "ede196e9e20a045f6037851d4a2e18f667e7adf0"}, "author": "", "url": "https://www.reuters.com/article/brief-bristol-myers-squibb-says-key-lung/brief-bristol-myers-squibb-says-key-lung-cancer-trial-meets-main-goal-idUSFWN1PV0V1", "ord_in_thread": 0, "title": "BRIEF-Bristol-Myers Squibb Says Key Lung Cancer Trial Meets Main Goal", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters) - bristol-myers squibb co", "sentiment": "none"}, {"name": "tmb", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 5, 2018 / 12:22 PM / in 18 minutes BRIEF-Bristol-Myers Squibb Says Key Lung Cancer Trial Meets Main Goal Reuters Staff 1 Min Read \nFeb 5 (Reuters) - Bristol-Myers Squibb Co: \n* PIVOTAL PHASE 3 CHECKMATE -227 STUDY DEMONSTRATES SUPERIOR PROGRESSION-FREE SURVIVAL (PFS) WITH THE OPDIVO PLUS YERVOY COMBINATION VERSUS CHEMOTHERAPY IN FIRST-LINE NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH HIGH TUMOR MUTATION BURDEN (TMB) \n* BRISTOL-MYERS - PHASE 3 CHECKMATE -227 STUDY MET CO-PRIMARY ENDPOINT OF PFS WITH OPDIVO PLUS YERVOY COMBINATION VERSUS CHEMOTHERAPY \n* BRISTOL-MYERS - TRIAL WILL CONTINUE AS PLANNED TO ASSESS OPDIVO-YERVOY COMBO FOR OTHER CO-PRIMARY ENDPOINT OF OVERALL SURVIVAL IN PATIENTS WITH PD-L1 TUMORS Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-05T14:19:00.000+02:00", "crawled": "2018-02-05T14:41:41.029+02:00", "highlightTitle": ""}